Gujarat Terce Laboratories Limited

Equities

524314

INE499G01013

Pharmaceuticals

Market Closed - Bombay S.E. 11:00:57 02/07/2024 BST 5-day change 1st Jan Change
46.99 INR +4.31% Intraday chart for Gujarat Terce Laboratories Limited -11.32% +64.94%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Gujarat Terce Laboratories Limited announced that it expects to receive INR 3.496675 million in funding CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Gujarat Terce Laboratories Limited Approves Appointment of Ripal Sachinkumar Sukhadiya as the Company Secretary & Compliance Officer CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Gujarat Terce Laboratories Limited Announces Resignation of Ashka Solanki as Company Secretary and Compliance Officer CI
Gujarat Terce Laboratories Limited Approves the Appointment of Natwarbhai Prajapati as the Whole Time Director CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Gujarat Terce Laboratories Appoints New CEO MT
Gujarat Terce Laboratories CEO Resigns MT
Gujarat Terce Laboratories Limited Announces Resignation of Natwarbhai Prajapati as Managing Director CI
Gujarat Terce Laboratories Limited Announces Executive Changes CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Gujarat Terce Laboratories : Turns to Profit in Fiscal Q1 MT
Gujarat Terce Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Gujarat Terce Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
Chart Gujarat Terce Laboratories Limited
More charts
Gujarat Terce Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of medicines and healthcare products. Its diverse portfolio encompasses approximately 70 brands and 180 stock-keeping units (SKUs) covering multiple dosage forms, such as tablets, capsules, oral liquids, ointments and injectables. The Company offers therapies in areas of antibiotics, gynecology, respiratory, nutraceuticals, gastrointestinal and anti-fungal. The Company’s brands include Acolate, Codimol, Resplash, Terflora Z, Thyter, Tynol, Z-Oxi, and Vitfol. The Company has approximately eight brands occupying a space in the top 10 in various therapeutic areas. The Company has a presence in over 13 states in India. The Company also has a presence in Eastern and Western Africa, the association of Southeast Asian Nations (ASEAN), and Latin American (LATAM) countries.
More about the company